To appraise the clinical and cost effectiveness of benralizumab within its marketing authorisation for treating inadequately controlled severe asthma with elevated blood eosinophils.
 
 
Status In progress
Process STA pre-2018
ID number 1129

Provisional Schedule

Appraisal consultation: 2 16 July 2018 - 06 August 2018

Project Team

Project lead Thomas Feist

Email enquiries

Consultees

Companies sponsors AstraZeneca
Others Department of Health
  Welsh Assembly Government
Patient carer groups Asthma UK
  British Thoracic Society

Commentators

Comparator companies GlaxoSmithKline
  Teva
General commentators British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland

Timeline

Key events during the development of the guidance:

Date Update
19 June 2018 Committee meeting: 2
11 May 2018 - 01 June 2018 Appraisal consultation: 1
17 April 2018 Committee meeting: 1
03 November 2017 In progress, Appraisal in progress
03 November 2017 Invitation to participate
29 March 2017 - 28 April 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance